Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C

Chan, Henry Lik‐Yuen; Ren, Hong; Chow, Wan Cheng; Wee, T.

doi:10.1002/hep.21683

Cited by 31 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such finding has also been observed in IFN-α therapy. 28 Recently, Chan et al 29 strongly supported the use of IFN-β-1a as an alternative to the IFN-α for Asian patients with chronic hepatitis C. The present study was more consistent with that from Cheng et al 21 since we would expect a much better response from the treatment-naïve population. The other interesting finding in our study was the trend toward a better response for IFN-β-1a therapy in the patients with higher baseline viral load.…”

supporting

confidence: 82%

Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study

et al. 2009

View full text Add to dashboard Cite

Background/Aims: Interferon beta (IFN-β) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-β (IFN-β-1a) plus oral ribavirin versus interferon alpha (IFN-α) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naïve patients were randomized into two equal-sized treatment groups. Both IFN-β-1a (44μg) and IFN-α (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-β-1a group and IFN-α groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-β-1a group than in the IFN-α group, and there were more HCV genotype 1 patients in the IFN-β-1a group (eight versus seven). The IFN-β-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-β-1a and ribavirin and that of IFN-α and ribavirin.

show abstract

supporting

confidence: 82%

Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Recent randomized trials demonstrated the efficacy of rhIFNβ-1a plus RBV (13,14). However, there is little information regarding nIFNβ plus RBV (15,16).…”

Section: Introduction Are Not Suitable Candidates For Ifnα Therapy (4mentioning

confidence: 99%

Natural Human Interferon .BETA. Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Recombinant human interferon-beta-1a and interferon-beta1b are produced in mammalian cells or Escherichia coli, respectively [57] . It was reported that recombinant human interferon-beta-1a with or without ribavirin has an excellent safety profile, and after 24-wk-treatment of recombinant human interferon-beta-1a with or without ribavirin, SVR was 21.6% and 27.4% in HCV genotype 1 and genotype 2 patients, respectively [57][58][59][60] . Peginterferonbeta-1a may be beneficial for patients infected with HCV [61,62] .…”

Section: Recombinant Interferon-betamentioning

confidence: 99%

Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Sasaki¹,

Nakamoto²,

Haga³

et al. 2015

WJH

View full text Add to dashboard Cite

Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C

Cited by 31 publications

References 31 publications

Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study

Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study

Natural Human Interferon .BETA. Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load

Natural interferon-beta treatment for patients with chronic hepatitis C in Japan

Contact Info

Product

Resources

About